Inogen Inc
Inogen is a medical technology company focused primarily on respiratory health. It develops, manufactures and markets portable oxygen concentrators, including its Inogen One and Inogen Rove systems, for patients who need long-term supplemental oxygen therapy. Its products also include the Inogen At Home and Voxi 5 stationary oxygen concentrators, Simeox airway clearance devices, and Aurora CPAP masks for treating obstructive sleep apnea. Inogen makes money by selling respiratory products to home medical equipment providers, distributors, resellers and consumers, and by renting oxygen systems directly to patients, billing Medicare and other insurers on their behalf. In the United States, it sells directly to consumers and through business customers; internationally, it sells through distributors, resellers and home medical equipment providers. Inogen manufactures oxygen concentrators in Plano, Texas, and Simeox in Montpelier, France.
No SEC Form 4 filings for $INGN in the last 30 days.
See all $INGN insider activity →Inogen (INGN) reported Q3 2026 earnings, with total revenue at $77.2M, U.S. sales up 3.8% YoY, and international sales down 9%. The company completed a divestiture of its U.S. oxygen rental business for up to $24.8M. Adjusted net loss was $400K, and a $20M cost savings program was announced to accelerate profitability. New CEO Andrew Reding emphasized growth and operational improvements.
Inogen reported a 2.4% revenue decline to $77.2M in Q3, with a $14.8M GAAP loss. The company sold its U.S. oxygen rental business and aims for $20M in annual savings. Andy Reding was named CEO, effective 2026, and the company plans governance changes for the 2027 shareholder meeting.
Inogen Inc. (INGN) reported a Q3 loss of $16.2M, or 61 cents per share, with adjusted losses of 56 cents per share. Revenue was $77.2M. The company expects full-year revenue between $298M and $301M.
Over the past 7 days, AlphAI's AI scored 10 news stories mentioning INGN (Inogen Inc). Coverage has skewed bearish: 0 bullish, 5 neutral, and 5 bearish.
Recent INGN coverage spans earnings, financial news and corporate actions.
Earnings miss but cost‑savings initiative may improve margins, creating modest upside potential.
The revenue decline and GAAP loss, combined with a leadership transition, suggest near‑term weakness for the stock.
Earnings miss and modest guidance likely weigh on the stock.
The new CEO appointment may improve execution and growth outlook, but immediate price impact is uncertain.
The appointment may be viewed as a positive step toward growth, but immediate price impact is likely modest.
AlphAI scores every news story that mentions INGN with an AI model for sentiment and relevance, and aggregates insider trades from Inogen Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Inogen (INGN) reported Q3 2026 earnings, with total revenue at $77.2M, U.S. sales up 3.8% YoY, and international sales down 9%. The company completed a divestiture of its U.S. oxygen rental business for up to $24.8M. Adjusted net loss was $400K, and a $20M cost savings program was announced to accelerate profitability. New CEO Andrew Reding emphasized growth and operational improvements.
Inogen reported a 2.4% revenue decline to $77.2M in Q3, with a $14.8M GAAP loss. The company sold its U.S. oxygen rental business and aims for $20M in annual savings. Andy Reding was named CEO, effective 2026, and the company plans governance changes for the 2027 shareholder meeting.
Inogen Inc. (INGN) reported a Q3 loss of $16.2M, or 61 cents per share, with adjusted losses of 56 cents per share. Revenue was $77.2M. The company expects full-year revenue between $298M and $301M.
Inogen Inc (INGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inogen Announces Leadership Transition Chief Operating Officer Andy Reding Appointed President and Chief Executive Officer BEVERLY, Mass., November 5, 2026 – Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use i
Inogen, Inc. (INGN) appointed Andy Reding as its new CEO, effective immediately. Reding, with over 30 years in medical technology, previously served as COO at Inogen and held leadership roles at Viant Medical and Hillrom. The company also announced its third-quarter 2026 financial results, to be released separately. Reding's appointment comes as Inogen aims to streamline operations and drive growth in respiratory therapy solutions, according to the board.
Inogen Inc (INGN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 INOGEN ANNOUNCES DIVESTITURE OF ITS U.S. OXYGEN RENTAL BUSINESS TO ROTECH Transaction advances Inogen’s strategic shift toward a more streamlined commercial model supporting higher revenue growth and adjusted operating income BEVERLY, Mass., September 30, 2026 -- Ino
Inogen (NASDAQ:INGN) reported Q2 results with improving profitability and continued international growth, but weakness in the US oxygen rental and direct-to-consumer channels. International revenue was $41.3M (+15% YoY). US sales fell 2% to $42.3M and rental revenue dropped 12% to $11.6M. Full-year 2026 revenue guidance was cut to $355M-$361M.
Inogen (INGN) reported Q2 2026 revenue of $95.1 million, up 3% year over year, driven by international sales of $41.3 million (+14.8%) and new product contributions. U.S. sales were $42.3 million, down 2.3%. Adjusted EBITDA was $2.4 million (+15.2%). Full-year revenue guidance was cut to $355-$361 million; adjusted EBITDA guidance is about $4 million. Cash was $106.8 million with zero debt.
Inogen (INGN) cut its 2026 revenue outlook to $355 million to $361 million from $366 million to $373 million after Q2 results showed ongoing U.S. channel pressure. Q2 U.S. sales fell 2.3% to $42.3M and U.S. rentals fell 11.8% to $11.6M, while international revenue rose 14.8% to $41.3M. Adjusted gross margin rose to 45.6%.
Inogen Inc (INGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inogen Announces Second Quarter 2026 Financial Results Reported second quarter revenue of $95.1 million Company raises full-year adjusted EBITDA guidance to approximately $4.0 million BEVERLY, Mass., August 6, 2026 -- Inogen, Inc. (Nasdaq: INGN ), a medical technolog
